4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-23-033394
Chief Executive Officer sold 25,000 shares at an average $64.88 ($1,621,894)
- Chief Executive Officer acquired 25,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2023-05-30 | Option exercise 10b5-1 | +25,000 | $19.12 | $478,000 | 412,377 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-05-30 | Sale 10b5-1 | −7,301 | $63.61 | $464,452 | 405,076 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-05-30 | Sale 10b5-1 | −5,999 | $64.46 | $386,682 | 399,077 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-05-30 | Sale 10b5-1 | −9,300 | $65.63 | $610,359 | 389,777 | D |
| Kulkarni Samarth Chief Executive Officer | 2023-05-30 | Sale 10b5-1 | −2,400 | $66.83 | $160,401 | 387,377 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2023-05-30 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 79,582 | D | ||
| Open-market sales · 25,000 sh · avg $64.88 · $1,621,894 | |||||||
Loading xslF345X04/doc4.xml…